Patents by Inventor Valeria G. Nicolini
Valeria G. Nicolini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092856Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunoconjugates with specific antibodies which bind human FAP and 4-1BB and optionally with an anti-CEA/anti-CD3 bispecific antibody.Type: ApplicationFiled: March 8, 2022Publication date: March 21, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Marina BACAC, Christina CLAUS, Laura CODARRI DEAK, Sara COLOMBETTI, Christian KLEIN, Valeria G. NICOLINI, Mario PERRO, Johannes SAM, Christine TRUMPFHELLER, Pablo UMAÑA
-
Publication number: 20240042022Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: September 8, 2023Publication date: February 8, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Ralf HOSSE, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMAÑA, Inja WALDHAUER, Wolfgang RICHTER, Alexander KNAUPP, Halina TROCHANOWSKA
-
Publication number: 20230277662Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: April 26, 2023Publication date: September 7, 2023Inventors: Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Ralf HOSSE, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMAÑA, Inja WALDHAUER, Wolfgang RICHTER, Alexander KNAUPP, Halina TROCHANOWSKA
-
Publication number: 20230181712Abstract: The present application provides methods for stimulating an immune response in an individual comprising administering a composition of nucleated cells (e.g., PBMCs) comprising an intracellular exogenous antigen in conjunction with administering an immunoconjugate comprising a variant IL-2 polypeptide and a second polypeptide. The variant IL-2 polypeptide exhibits reduced affinity to the ?-subunit of the IL-2 receptor. The second polypeptide targets a tumor cell or a T cell.Type: ApplicationFiled: May 10, 2021Publication date: June 15, 2023Inventors: Pablo UMAÑA, Christian KLEIN, Christine TRUMPFHELLER, Valeria G. NICOLINI, Laura CODARRI DEAK, Scott LOUGHHEAD, Matthew BOOTY
-
Patent number: 11672858Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: GrantFiled: December 19, 2019Date of Patent: June 13, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Anne Freimoser-Grundschober, Thomas Hofer, Ralf Hosse, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umaña, Inja Waldhauer, Wolfgang Richter, Alexander Knaupp, Halina Trochanowska
-
Publication number: 20230134606Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: June 30, 2022Publication date: May 4, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
-
Patent number: 11591397Abstract: The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: GrantFiled: September 14, 2021Date of Patent: February 28, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Anne Freimoser-Grundschober, Thomas Hofer, Ralf Hosse, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umaña, Inja Waldhauer, Wolfgang Richter, Alexander Knaupp, Halina Trochanowska
-
Publication number: 20220281995Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.Type: ApplicationFiled: May 13, 2022Publication date: September 8, 2022Applicant: Roche Glycart AGInventors: Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMANA
-
Patent number: 11413331Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: GrantFiled: April 2, 2018Date of Patent: August 16, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
-
Patent number: 11332545Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.Type: GrantFiled: April 8, 2019Date of Patent: May 17, 2022Assignee: ROCHE GLYCART AGInventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
-
Publication number: 20210403562Abstract: The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: September 14, 2021Publication date: December 30, 2021Inventors: Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Ralf HOSSE, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMAÑA, Inja WALDHAUER, Wolfgang RICHTER, Alexander KNAUPP, Halina TROCHANOWSKA
-
Patent number: 11111312Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: GrantFiled: November 21, 2018Date of Patent: September 7, 2021Assignee: ROCHE GLYCART AGInventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
-
Publication number: 20200270347Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: December 19, 2019Publication date: August 27, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Ralf HOSSE, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMAÑA, lnja WALDHAUER, Wolfgang Richter, Alexander KNAUPP, Halina TROCHANOWSKA
-
Publication number: 20200197492Abstract: The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.Type: ApplicationFiled: March 2, 2020Publication date: June 25, 2020Applicant: Roche Glycart AGInventors: Christian GERDES, Christian KLEIN, Valeria G. NICOLINI, Pablo UMANA
-
Publication number: 20200188526Abstract: The invention provides compositions and methods for treating cancer, the method comprising administering an IL-2 immunoconjugate, a CD40 agonist and optionally a PD-1 axis binding antagonist.Type: ApplicationFiled: October 8, 2019Publication date: June 18, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Christian KLEIN, Valeria G. NICOLINI, Pablo UMAÑA
-
Patent number: 10603360Abstract: The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.Type: GrantFiled: November 16, 2016Date of Patent: March 31, 2020Assignee: Roche Glycart AGInventors: Christian Gerdes, Christian Klein, Valeria G. Nicolini, Pablo Umana
-
Publication number: 20200079873Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.Type: ApplicationFiled: April 8, 2019Publication date: March 12, 2020Applicant: Roche Glycart AGInventors: Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMANA
-
Patent number: 10577429Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.Type: GrantFiled: March 18, 2015Date of Patent: March 3, 2020Assignee: ROCHE GLYCART AGInventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
-
Publication number: 20190374609Abstract: The present invention relates to the combination therapy of specific tumor-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.Type: ApplicationFiled: August 15, 2019Publication date: December 12, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Pablo Umana, Christian Klein, Valeria G. Nicolini
-
Publication number: 20190322765Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: June 17, 2019Publication date: October 24, 2019Applicant: Roche Glycart AGInventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana